ProQR (PRQR) AI Stock Analysis

• Market Cap: $222.00M
• Dividend Yield: N/A
• Average Volume (3M): 373.99K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.72
• Revenue Growth: 7.59%
• EPS Growth: -53.46%
• Country: US
• Employees: 166
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.14
• Shares Outstanding: 105,212,524
• 10 Day Avg. Volume: 381,360
• 30 Day Avg. Volume: 373,990
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.41
• Enterprise Value/Revenue: 5.58
• Enterprise Value/Gross Profit: 5.58
• Enterprise Value/Ebitda: -2.58
• 1Y Price Target: $8.33
• Price Target Upside: 291.08% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 45 Neutral
• Price Target: $2.00 ▼(-6.10% Downside)

ProQR's overall stock score is primarily impacted by its financial performance, which shows significant challenges with declining revenue and persistent losses. Technical analysis provides mixed signals, with some short-term bullish momentum but potential bearish pressure. Valuation remains unattractive due to a negative P/E ratio and lack of dividend yield. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Innovative RNA Technology

ProQR's proprietary RNA technology platform positions it as a leader in developing transformative treatments for genetic diseases, offering a durable competitive advantage in the biotechnology sector.

R&D Collaborations

Collaborations with pharmaceutical companies and research institutions provide ProQR with diverse revenue streams and enhance its R&D capabilities, supporting long-term growth potential and innovation.

High Gross Profit Margin

A high gross profit margin indicates strong pricing power and efficient production processes, which can support sustained profitability as the company scales its operations.

Negative Factors

Declining Revenue

Declining revenue poses a significant challenge to ProQR's financial health, potentially impacting its ability to invest in R&D and maintain competitive positioning in the long term.

Negative Cash Flow

Negative operating cash flow indicates liquidity challenges, which can constrain ProQR's ability to fund ongoing operations and strategic initiatives, impacting long-term sustainability.

Persistent Losses

Ongoing financial losses highlight operational inefficiencies and may undermine investor confidence, posing a risk to ProQR's ability to secure future funding and achieve profitability.

ProQR Business Overview & Revenue Model

Company Description

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

How the Company Makes Money

ProQR generates revenue primarily through a combination of product sales, research and development collaborations, and licensing agreements. The company partners with pharmaceutical companies and research institutions to co-develop therapies, which can provide upfront payments, milestone payments, and royalties on future sales of products developed through these collaborations. Additionally, ProQR may receive funding through grants and investments aimed at advancing its clinical programs. As its drug candidates progress through clinical trials and gain regulatory approvals, the potential for revenue increases significantly, particularly if successful therapies are commercialized.

ProQR Financial Statement Overview

Summary

ProQR faces significant financial challenges, with declining revenue and persistent losses impacting profitability. The balance sheet shows moderate leverage, but negative returns on equity highlight ongoing financial struggles. Cash flow improvements are limited, with negative operating cash flow posing risks to financial stability. Overall, the company needs to address its profitability and cash flow issues to improve its financial health.

Income Statement

ProQR's income statement reveals significant challenges, with negative net profit margins and declining revenue growth. The TTM data shows a revenue decline of 13.26%, and net profit margins are deeply negative at -158.81%. Despite a high gross profit margin of 96.24%, the company struggles with profitability, as evidenced by negative EBIT and EBITDA margins.

Balance Sheet

The balance sheet indicates moderate leverage with a debt-to-equity ratio of 0.21 in the TTM period. However, the return on equity is negative at -53.58%, reflecting ongoing losses. The equity ratio is not provided, but the company's financial stability is under pressure due to consistent negative returns.

Cash Flow

Cash flow analysis shows a slight improvement in free cash flow growth at 13.11% in the TTM period. However, operating cash flow remains negative, and the operating cash flow to net income ratio is -1.10, indicating cash flow challenges. The free cash flow to net income ratio is slightly positive at 1.02, suggesting some alignment between cash flow and net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	16.49M	18.91M	6.51M	4.04M	1.35M	0.00
Gross Profit	16.49M	18.91M	6.38M	1.56M	1.35M	-2.19M
EBITDA	-35.70M	-24.12M	-24.10M	-56.46M	-54.95M	-136.56M
Net Income	-39.67M	-27.76M	-28.12M	-64.89M	-61.68M	-46.61M
Balance Sheet
Total Assets	137.54M	167.96M	137.88M	171.32M	209.58M	98.73M
Cash, Cash Equivalents and Short-Term Investments	119.77M	149.41M	118.92M	94.78M	187.52M	75.84M
Total Debt	16.86M	17.22M	19.73M	21.97M	60.37M	34.28M
Total Liabilities	70.55M	79.40M	96.49M	106.21M	96.35M	42.18M
Stockholders Equity	66.98M	88.56M	41.39M	65.50M	113.83M	57.09M
Cash Flow
Free Cash Flow	-42.95M	-37.81M	20.18M	-69.22M	-26.50M	-47.98M
Operating Cash Flow	-42.20M	-36.39M	21.55M	-68.51M	-26.01M	-47.06M
Investing Cash Flow	13.60M	-4.07M	4.28M	-702.00K	-425.00K	-924.00K
Financing Cash Flow	70.18M	70.28M	-2.27M	-30.89M	136.83M	14.50M

ProQR Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2.13
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRQR, the sentiment is Neutral. The current price of 2.13 is below the 20-day moving average (MA) of 2.19, below the 50-day MA of 2.16, and above the 200-day MA of 2.04, indicating a neutral trend. The MACD of -0.02 indicates Positive momentum. The RSI at 48.26 is Neutral, neither overbought nor oversold. The STOCH value of 83.91 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PRQR.

ProQR Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TNXP	57 Neutral	$217.04M	-0.02	-93.18%	―	-21.09%	90.95%
CGEN	52 Neutral	$134.69M	-6.99	-25.92%	―	-48.16%	-97.37%
SEER	52 Neutral	$124.51M	-1.56	-26.44%	―	12.13%	-8.23%
SLN	48 Neutral	$267.82M	-3.10	-33.81%	―	―	―
PRQR	45 Neutral	$222.00M	―	-75.99%	―	7.59%	-53.46%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

ProQR Corporate Events

ProQR Reports Q2 2025 Financial Results Amid Rising R&D Costs

On August 7, 2025, ProQR Therapeutics N.V. announced its financial results for the second quarter of 2025, ending June 30. The company reported a decrease in revenue compared to the previous year, alongside increased research and development costs, leading to a significant operating loss. This financial performance may impact ProQR’s market positioning and stakeholder confidence as the company navigates the challenges of developing treatments for rare genetic disorders.

ProQR Submits CTA for Phase 1 Study of AX-0810

On June 26, 2025, ProQR Therapeutics announced the submission of a Clinical Trial Application (CTA) to the European Medicines Agency for a Phase 1 clinical trial of AX-0810, targeting NTCP, a liver cell protein. This marks a significant milestone as it is the first clinical application of ProQR’s Axiomer RNA editing platform. The trial will evaluate the safety and pharmacokinetics of AX-0810 in healthy volunteers, with initial data expected in Q4 2025. This development is crucial for ProQR’s positioning in the RNA therapy industry, potentially offering a novel therapeutic approach for cholestatic liver diseases.